Blueprint Medicines News

Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Aug 1 19:31

Blueprint Medicines | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Jun 22 04:41

Blueprint Medicines | 8-K: Current report

Jun 15 04:06

Blueprint Medicines | 8-K: Current report

May 24 20:01

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

May 2 19:13

Blueprint Medicines | DEF 14A: Definitive information statements

Apr 26 05:26

Blueprint Medicines | 8-K: Current report

Apr 25 20:35

Blueprint Medicines | 8-K: Current report

Feb 22 21:21

Blueprint Medicines | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Feb 17 05:43

Blueprint Medicines | 8-K: Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results

Feb 15 20:07

Blueprint Medicines | 8-K: Current report

Jan 8 13:00

Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2023 Results

Oct 26, 2023 19:00

Blueprint Medicines | 8-K: Current report

Aug 25, 2023 20:15

Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2023 Results

Aug 2, 2023 19:00

Blueprint Medicines | 8-K: Current report

Jun 30, 2023 18:03

Blueprint Medicines | 8-K: Current report

Jun 28, 2023 04:01

Blueprint Medicines | 8-K: Current report

May 26, 2023 04:32

Blueprint Medicines | 8-K: Current report

May 23, 2023 04:53

Blueprint Medicines | 8-K: Blueprint Medicines Reports First Quarter 2023 Results

May 4, 2023 19:18

Blueprint Medicines | DEFA14A: Others

Apr 29, 2023 05:30